Azelnidipine
Alternative Names: Calblock; CS 905; RS 9054Latest Information Update: 05 Nov 2023
At a glance
- Originator Daiichi Sankyo Company; Ube Industries
- Class Antihypertensives; Dihydropyridines; Imino acids
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 23 May 2003 First global launch of Azelnidipine
- 23 May 2003 Launched for Hypertension in Japan (PO)